Trial reportBritish journal of cancer2011
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Trial report in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: A meta-analysis.Medicine · 2018Pooled it
- Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.The Lancet. Oncology · 2015Trial
- Progress in the Treatment of Small Intestine Cancer.Current treatment options in oncology · 2023Review
- Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.Journal of clinical medicine · 2023Review
- Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.Journal of neuroendocrinology · 2022Article
- Chemotherapy in NEN: still has a role?Reviews in endocrine & metabolic disorders · 2021Review
- Medical Management of Gastroenteropancreatic Neuroendocrine Tumors.Surgical oncology clinics of North America · 2020Review
- Management of Small Bowel Neuroendocrine Tumors.Cancers · 2019Review
- Management of Gastrointestinal Neuroendocrine Tumors.Clinical medicine insights. Endocrinology and diabetes · 2019Review
- Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.Journal of thoracic disease · 2018Article
- Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary.Journal of oncology · 2018Article
- Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors.OncoTargets and therapy · 2016Review
- Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs.Journal of gastrointestinal oncology · 2014Article
- Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.British journal of cancer · 2014Article
- Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature.OncoTargets and therapy · 2014Article
- Occult primary medullary thyroid carcinoma presenting with pituitary and parotid metastases: case report and review of the literature.Endocrine pathology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThis study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs).
methodsMulticentre phase II, first-line study design. Oral capecitabine was administered on days 1-14 of 3-week cycles.
resultsTreatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue.
conclusionThe study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.